| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Concord is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
JOM Pharmaceutical Services is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zila, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Innovative Seating Solutions manufactures custom-fitted chairs, back orthotics and seat cushions to relieve pain and enhance seating comfort.